SARDOCOR

What this means for you

Approved and waiting on proof of use. It will register unless the applicant drops it, and its 11 Feb 2025 filing date already counts against anyone who files later.

Record

Serial number

99036195

Mark type

Stylized text

Filed

11 Feb 2025

Published for opposition

02 Sept 2025

Attorney of record

Anna Kurian Shaw

Goods and services

• Class 005 — Pharmaceuticals: Adhesive plasters for medical purposes; biological tissue cultures for medical purposes; biological tissue cultures for veterinary purposes; cardiovascular agents for medical purposes; cardiovascular medicines; cells for medical or clinical use; cells for medical purposes; chemical reagents for medical or veterinary purposes for use in gene and cell therapies for the treatment of cardiovascular diseases and systemic diseases associated with cardiac pathology; diagnostic preparations for medical purposes for use in gene and cell therapies for the treatment of cardiovascular diseases and systemic diseases associated with cardiac pathology; dietary supplements for humans; dietary supplements for pets in the form of treats; dietetic foods adapted for medical purposes; disinfectants; food for babies; fungicides; gene therapy products, namely, genetically engineered tissues for transplant purposes; herbicides; medicinal preparations for regenerative and reparative therapies; nucleic acid sequences and chemical reagents for medical and veterinary purposes; pharmaceutical preparations for the treatment of heart rhythm disorders; pharmaceutical preparations for the treatment of respiratory diseases; pharmaceutical preparations, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; preparations for destroying vermin; sanitary preparations for medical use; sanitary preparations for veterinary use; stem cells for medical purposes; stem cells for veterinary purposes; surgical implants comprised of living tissues; synthetic peptides for pharmaceutical purposes; synthetic peptides for the treatment of respiratory conditions; veterinary preparations for regenerative and reparative therapies; pharmaceutical preparations for the treatment of heart disorders and systemic diseases associated with cardiac pathology; pharmaceutical preparations, namely, drugs for the prevention and treatment of cardiovascular diseases and systemic diseases associated with cardiac pathology; living cells for medical purpose
• Class 042 — Scientific and technological services: Bacteriological research for use in gene and cell therapies for the treatment of cardiovascular diseases and systemic diseases associated with cardiac pathology; biological research for use in gene and cell therapies for the treatment of cardiovascular diseases and systemic diseases associated with cardiac pathology; biomedical research services for use in gene and cell therapies for the treatment of cardiovascular diseases and systemic diseases associated with cardiac pathology; biotechnology research for use in gene and cell therapies for cardiovascular diseases and systemic diseases associated with cardiac pathology; chemical research for use in gene and cell therapies for the treatment of cardiovascular diseases and systemic diseases associated with cardiac pathology; medical and scientific research in the nature of conducting clinical trials for others; scientific research in the nature of conducting clinical trials for others in the field of gene and cell therapies for the treatment of cardiovascular diseases and systemic diseases associated with cardiac pathology; conducting early evaluations in the field of new pharmaceuticals for gene and cell therapies for the treatment of cardiovascular diseases and systemic diseases associated with cardiac pathology; research and development in the field of of biopharmaceutical products and medicine for gene and cell therapies for the treatment of cardiovascular diseases and systemic diseases associated with cardiac pathology; drug discovery services; engineering services, particularly technical project planning and design engineering of lines for the processing of web products; industrial research in the field of regenerative and reparative therapies; medical and pharmaceutical research services in the field of gene and cell therapies for the treatment of cardiovascular diseases and systemic diseases associated with cardiac pathology; medical research laboratory services; pharmaceutical research services; pharmaceutical drug development services for gene and cell therapies for the treatment of cardiovascular diseases and systemic diseases associated with cardiac pathology; pharmaceutical product evaluation and analysis; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; research and development and consultation related thereto in the field of genetic and cellular modulation techniques for cardiovascular applications; research and development of new products for others; research and development of vaccines and medicines for gene and cell therapies for the treatment of cardiovascular diseases and systemic diseases associated with cardiac pathology; conducting scientific research in the field of gene therapy; stem cell research services; technical research in the field of pharmaceutical studies; technological research in the field of regenerative and therapies
• Class 044 — Medical, beauty and agricultural services: Blood bank services; healthcare services; human tissue bank services; medical care services; medical services; medical testing and medical evaluation of cardiovascular diseases and systemic diseases associated with cardiac pathology; organ and tissue bank services; stem cell therapy services; medical services in the field of cardiovascular diseases; consultancy services in the field of cardiovascular diseases

Owner

• Sardocor Corp., Boston, MA, US
• Sardocor Corp., Boston, MA, US

Prosecution history

• 28 Oct 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
• 02 Sept 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
• 02 Sept 2025 — PUBLISHED FOR OPPOSITION
• 27 Aug 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
• 28 Jul 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
• 23 Jul 2025 — EXAMINER'S AMENDMENT ENTERED
• 23 Jul 2025 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
• 23 Jul 2025 — EXAMINERS AMENDMENT E-MAILED
• 23 Jul 2025 — EXAMINERS AMENDMENT -WRITTEN
• 18 Jul 2025 — ASSIGNED TO EXAMINER
• 09 Jul 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
• 11 Feb 2025 — APPLICATION FILING RECEIPT MAILED
• 11 Feb 2025 — NEW APPLICATION ENTERED